Skip to content
stoqly

Haemonetics

HAE NYSE Health Care Supplies Financials FY2017–FY2026

Haemonetics' revenue fell 2.0% to $1.3 billion in fiscal 2026. Its operating margin was 11.8%, down from 16.3% a year earlier. Free cash flow was $260 million, up 82.8%. It paid out $175 million in dividends and buybacks, 67% of free cash flow. The diluted share count fell 6.7%.

Last close · Oct 23, 2026

$118.51

2.0%
Value it Compare
Revenue Total sales reported in the income statement.
$1.3B
2.0% vs prior year
Operating margin Operating income as a share of revenue.
11.8%
4.6 pts
Net income Profit after all expenses, interest and tax.
$97.3M
42.0%
Free cash flow Cash from operations minus capital spending.
$260M
82.8%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
6.7%
3.8 pts
Market cap Last close times the latest diluted share count, so it is approximate.
$5.4B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
57.3x
On $2.07 EPS (TTM)

What Haemonetics does

No business description yet.

Legal name
Haemonetics Corporation
Fiscal year ends
March 28, 2026
Latest annual report
—
Accession · CIK
0000313143-26-000050
0000313143

Revenue and margins

Haemonetics had $1.3B of revenue in fiscal 2026, down 2.0% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $260M in fiscal 2026, 19.5% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Haemonetics returned $175M to shareholders in fiscal 2026, 67% of free cash flow. The diluted share count fell 6.7%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Haemonetics yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of −$994M and divides by 47.4M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

—

Reference multiples: today 57.3x · peers 45.5x · sector 27.9x.

Balance sheet

Cash, debt and the ratios that show how comfortably Haemonetics can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments $260M$285M$179M$307M$245M
Debt incl. finance leases $774M$766M$808M$1.2B$1.2B
Net debt / EBITDA 2.9x1.9x2.4x2.8x3.7x
Debt / equity 1.0x0.9x0.8x1.5x1.6x
Interest coverage 13.9x12.0x8.5x6.2x8.1x
Current ratio 1.7x3.1x2.6x1.6x3.0x
Quick ratio 1.1x2.0x1.5x1.0x1.9x
Total assets $1.9B$1.9B$2.2B$2.5B$2.4B
Total liabilities $1.1B$1.1B$1.2B$1.6B$1.6B
Shareholders' equity $749M$818M$960M$821M$796M
Net debt (− = net cash) $514M$481M$629M$939M$994M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.1M

1 insider

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

DateInsiderTradeSharesPriceValueFiling
Nov 10, 2025 Mark W KrollDirector Bought 1,400 $70.56 $0.1M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY24FY25FY26
Net income is positive ✓ ✓ ✓
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✕ ✓ ✕
Cash from operations exceeds net income ✓ ✓ ✓
Debt fell relative to assets ✓ ✕ ✓
Current ratio rose ✕ ✕ ✓
Share count didn't rise ✓ ✓ ✓
Gross margin rose ✓ ✓ ✓
Revenue rose relative to assets ✓ ✕ ✕
F-score 7 / 96 / 97 / 9
Accruals ratio −3.1%−0.6%−8.1%
Altman Z'' 3.262.562.85

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Haemonetics HAE $5.4B −2.0% 11.8% 19.5% 6.7% 57.3x 7
Lantheus LNTH $6.7B 0.5% 20.2% 23.0% 22.7% 24.2x 5 Compare →
ICU Medical ICUI $4.2B −6.3% 1.9% 4.1% 0.7% 140.0x 6 Compare →
Envista NVST $3.9B 8.3% 8.0% 8.5% 3.2% 40.7x 7 Compare →
West Pharmaceutical Services WST $28.0B 6.3% 19.0% 15.3% 18.7% 50.2x 9 Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Income statement
Revenue $886M $904M $968M $989M $871M $993M $1.2B $1.3B $1.4B $1.3B
Gross profit $379M $412M $418M $485M $398M $506M $615M $692M $749M $788M
Research and development $37.6M $39.2M $35.7M $30.9M $32.9M $46.8M $50.1M $54.4M $62.7M $59.8M
Operating income −$19.4M $56.2M $83.5M $103M $89.7M $80.8M $156M $165M $222M $157M
Interest expense $7.8M $7.7M $12.6M $13.5M $9.4M $5.8M $13.0M $19.5M $35.9M $19.3M
Pretax income −$27.5M $59.6M $73.6M $87.2M $72.9M $63.6M $141M $152M $212M $128M
Income tax −$1.2M $14.1M $18.6M $10.6M −$6.6M $20.3M $26.0M $34.3M $44.4M $30.7M
Net income −$26.3M $45.6M $55.0M $76.5M $79.5M $43.4M $115M $118M $168M $97.3M
Diluted EPS −$0.51 $0.85 $1.04 $1.48 $1.55 $0.84 $2.24 $2.29 $3.31 $2.05
Diluted shares 0.05B 0.05B 0.05B 0.05B 0.05B 0.05B 0.05B 0.05B 0.05B 0.05B
Cash flow
Cash from operations $160M $220M $159M $158M $109M $172M $273M $182M $182M $293M
Capital expenditure $76.1M $74.8M $119M $48.8M $37.0M $96.5M $191M $38.1M $39.3M $32.8M
Free cash flow $83.6M $146M $40.3M $109M $71.8M $75.8M $81.7M $144M $142M $260M
Depreciation and amortization $89.7M $89.2M $109M $110M $84.3M $97.7M $93.3M $97.2M $116M $112M
Stock-based compensation $9.2M $13.0M $17.2M $20.5M $25.5M $24.4M $25.6M $28.3M $29.6M $33.8M
Acquisitions $0.0M $0.0M $0.0M $0.0M $435M $2.5M $2.9M $244M $151M $60.2M
Share buybacks $0.0M $100M $160M $175M $0.0M $0.0M $75.0M $0.0M $225M $175M
Dividends paid $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends and buybacks $0.0M $100M $160M $175M $0.0M $0.0M $75.0M $0.0M $225M $175M
Balance sheet
Cash and short-term investments $140M $180M $169M $137M $192M $260M $285M $179M $307M $245M
Total debt $316M $254M $350M $383M $708M $774M $766M $808M $1.2B $1.2B
Finance lease liabilities $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Current assets $510M $521M $576M $604M $694M $756M $770M $769M $935M $835M
Current liabilities $211M $385M $236M $275M $254M $442M $252M $300M $578M $283M
Inventory $177M $161M $194M $270M $323M $293M $259M $317M $365M $306M
Property and equipment, net $324M $332M $344M $253M $218M $259M $311M $311M $284M $306M
Total assets $1.2B $1.2B $1.3B $1.3B $1.8B $1.9B $1.9B $2.2B $2.5B $2.4B
Total liabilities $499M $485M $607M $680M $1.1B $1.1B $1.1B $1.2B $1.6B $1.6B
Shareholders' equity $740M $752M $668M $587M $732M $749M $818M $960M $821M $796M
Margins
Gross margin 42.7% 45.6% 43.2% 49.0% 45.7% 50.9% 52.6% 52.8% 55.0% 59.0%
Operating margin −2.2% 6.2% 8.6% 10.5% 10.3% 8.1% 13.4% 12.6% 16.3% 11.8%
EBITDA margin 7.9% 16.1% 19.9% 21.6% 20.0% 18.0% 21.3% 20.0% 24.8% 20.1%
Net margin −3.0% 5.0% 5.7% 7.7% 9.1% 4.4% 9.9% 9.0% 12.3% 7.3%
FCF margin 9.4% 16.1% 4.2% 11.1% 8.2% 7.6% 7.0% 11.0% 10.5% 19.5%
Returns
Return on capital −1.6% 4.9% 7.5% 10.8% 8.6% 4.4% 9.9% 8.8% 10.5% 6.7%
Return on capital employed −1.8% 6.0% 8.8% 10.2% 7.0% 5.4% 10.1% 9.2% 11.8% 7.9%
Return on equity −3.6% 6.1% 7.8% 12.2% 12.1% 5.9% 14.7% 13.2% 18.8% 12.0%
Return on assets −2.1% 3.7% 4.4% 6.0% 5.2% 2.4% 6.1% 5.7% 7.2% 4.0%
Growth
Revenue growth −2.5% 2.0% 7.0% 2.2% −11.9% 14.1% 17.7% 12.0% 4.0% −2.0%
Net income growth — — 20.7% 39.1% 3.9% −45.4% 166.1% 1.9% 42.6% −42.0%
EPS growth — — 22.4% 42.3% 4.7% −45.8% 166.7% 2.2% 44.5% −38.1%
FCF growth 329.6% 74.1% −72.3% 171.5% −34.4% 5.6% 7.9% 75.7% −0.8% 82.8%
Share count change 1.2% 3.8% −1.0% −2.1% −1.0% 0.1% 0.1% −0.0% −1.3% −6.7%
Financial health
Net debt / EBITDA 2.5x 0.5x 0.9x 1.2x 3.0x 2.9x 1.9x 2.4x 2.8x 3.7x
Debt / equity 0.4x 0.3x 0.5x 0.7x 1.0x 1.0x 0.9x 0.8x 1.5x 1.6x
Interest coverage −2.5x 7.3x 6.6x 7.7x 9.6x 13.9x 12.0x 8.5x 6.2x 8.1x
Current ratio 2.4x 1.4x 2.4x 2.2x 2.7x 1.7x 3.1x 2.6x 1.6x 3.0x
Quick ratio 1.6x 0.9x 1.6x 1.2x 1.5x 1.1x 2.0x 1.5x 1.0x 1.9x
Capital allocation
Capex / revenue 8.6% 8.3% 12.3% 4.9% 4.3% 9.7% 16.4% 2.9% 2.9% 2.5%
Stock comp / revenue 1.0% 1.4% 1.8% 2.1% 2.9% 2.5% 2.2% 2.2% 2.2% 2.5%
Payouts / FCF 0.0% 68.7% 396.8% 159.9% 0.0% 0.0% 91.8% 0.0% 158.0% 67.2%
Quality scores
Piotroski F-score 5.0 7.0 7.0 6.0 6.0 5.0 8.0 7.0 6.0 7.0
Altman Z'' 3.8 3.4 3.8 3.4 2.9 2.5 3.5 3.3 2.6 2.9
Accruals ratio −14.5% −14.1% −8.3% −6.4% −1.9% −7.0% −8.3% −3.1% −0.6% −8.1%

Source: SEC EDGAR XBRL filings (CIK 0000313143). Data updated October 14, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open